JP2010506926A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506926A5
JP2010506926A5 JP2009533371A JP2009533371A JP2010506926A5 JP 2010506926 A5 JP2010506926 A5 JP 2010506926A5 JP 2009533371 A JP2009533371 A JP 2009533371A JP 2009533371 A JP2009533371 A JP 2009533371A JP 2010506926 A5 JP2010506926 A5 JP 2010506926A5
Authority
JP
Japan
Prior art keywords
mhc class
pharmaceutical formulation
residue
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009533371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506926A (ja
Filing date
Publication date
Priority claimed from US11/582,596 external-priority patent/US20080095798A1/en
Application filed filed Critical
Publication of JP2010506926A publication Critical patent/JP2010506926A/ja
Publication of JP2010506926A5 publication Critical patent/JP2010506926A5/ja
Pending legal-status Critical Current

Links

JP2009533371A 2006-10-18 2007-10-18 Ｉｉ−Ｋｅｙ増強ワクチンの効力 Pending JP2010506926A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/582,596 US20080095798A1 (en) 2006-10-18 2006-10-18 Ii-key enhanced vaccine potency
PCT/US2007/022230 WO2008060385A2 (en) 2006-10-18 2007-10-18 Li-key enhanced vaccine potency

Publications (2)

Publication Number Publication Date
JP2010506926A JP2010506926A (ja) 2010-03-04
JP2010506926A5 true JP2010506926A5 (OSRAM) 2010-11-25

Family

ID=39318185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533371A Pending JP2010506926A (ja) 2006-10-18 2007-10-18 Ｉｉ−Ｋｅｙ増強ワクチンの効力

Country Status (5)

Country Link
US (1) US20080095798A1 (OSRAM)
EP (1) EP2081591A4 (OSRAM)
JP (1) JP2010506926A (OSRAM)
CA (1) CA2666342A1 (OSRAM)
WO (1) WO2008060385A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
EP2117558A4 (en) * 2007-01-26 2013-04-03 Univ Colorado METHOD FOR MODULATING THE IMMUNO FUNCTION
EP2215108A4 (en) 2007-10-23 2012-07-04 Univ Colorado COMPETITIVE INHIBITORS OF THE EXPRESSION OF THE CONSTANT CHAIN AND / OR THE ECTOPIC CLIP BINDING
CA2730773A1 (en) 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
WO2010011315A2 (en) * 2008-07-25 2010-01-28 Viral Genetics, Inc. Proteins for use in diagnosing and treating infection and disease
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
JP5707326B2 (ja) * 2008-09-02 2015-04-30 アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
DK2865387T3 (da) * 2008-11-21 2019-08-26 Univ Copenhagen Forberedelse af en immunreaktion
JP2012516350A (ja) * 2009-01-28 2012-07-19 アンティジェン・エクスプレス・インコーポレーテッド インフルエンザに対する免疫応答を調節するＩｉ−Ｋｅｙハイブリッドペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
JP2006515744A (ja) * 2002-09-17 2006-06-08 アンテイジエン・エクスプレス・インコーポレーテツド Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン

Similar Documents

Publication Publication Date Title
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
JP2010506926A5 (OSRAM)
Adar et al. A universal epitope-based influenza vaccine and its efficacy against H5N1
Zheng et al. Development of universal influenza vaccines based on influenza virus M and NP genes
JP2021001216A (ja) インフルエンザ抗原送達用のベクターおよび構築体
Lo et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
JP2006527762A5 (OSRAM)
JP2008530245A5 (OSRAM)
TR201908199T4 (tr) HPV'ye karşı aşılar.
CN101636177A (zh) 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗
JP2008529558A5 (OSRAM)
JP2010502207A5 (OSRAM)
WO2009073330A3 (en) Novel vaccines against multiple subtypes of influenza virus
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
RU2017137357A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
JP2009504654A5 (OSRAM)
JP2014523878A5 (OSRAM)
JP2013518052A5 (OSRAM)
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
Du et al. Flu universal vaccines: new tricks on an old virus
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
WO2008060385A3 (en) Li-key enhanced vaccine potency
Cossette et al. Intranasal subunit vaccination strategies employing nanomaterials and biomaterials
ATE465753T1 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
Zhao et al. Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses